SAREPTA THERAPEUTICS, INC. Additional Paid in Capital, Common Stock
SAREPTA THERAPEUTICS, INC. (SRPT) had Additional Paid in Capital, Common Stock of $6.10 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-05
- 2026-06-30: Additional Paid in Capital, Common Stock $6.10B.
- 2026-03-31: Additional Paid in Capital, Common Stock $6.08B.
- 2025-12-31: Additional Paid in Capital, Common Stock $6.04B.
- 2025-09-30: Additional Paid in Capital, Common Stock $5.99B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $6.10B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $6.08B 10-Q · filed 2026-05-06 |
| 2025-12-31 | $6.04B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $5.99B 10-Q · filed 2025-11-06 |
| 2025-06-30 | $5.84B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $5.80B 10-Q · filed 2025-05-06 |
| 2024-12-31 | $5.74B 10-K · filed 2026-03-02 |
| 2024-09-30 | $5.59B 10-Q · filed 2024-11-06 |
| 2024-06-30 | $5.48B 10-Q · filed 2024-08-07 |
| 2024-03-31 | $5.37B 10-Q · filed 2024-05-01 |
| 2023-12-31 | $5.30B 10-K · filed 2025-02-28 |
| 2023-09-30 | $5.26B 10-Q · filed 2023-11-01 |
| 2023-06-30 | $5.19B 10-Q · filed 2023-08-02 |
| 2023-03-31 | $5.14B 10-Q · filed 2023-05-02 |
| 2022-12-31 | $4.30B 10-K · filed 2024-02-28 |
| 2022-09-30 | $4.24B 10-Q · filed 2022-11-02 |
| 2022-06-30 | $4.27B 10-Q · filed 2022-08-02 |
| 2022-03-31 | $4.17B 10-Q · filed 2022-05-04 |
| 2021-12-31 | $4.13B 10-K · filed 2023-02-28 |
| 2021-09-30 | $3.55B 10-Q · filed 2021-11-03 |
| 2021-06-30 | $3.52B 10-Q · filed 2021-08-04 |
| 2021-03-31 | $3.49B 10-Q · filed 2021-05-05 |
| 2020-12-31 | $3.61B 10-K · filed 2022-03-01 |
| 2020-09-30 | $3.55B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $3.51B 10-Q · filed 2020-08-05 |
| 2020-03-31 | $3.46B 10-Q · filed 2020-05-06 |
| 2019-12-31 | $3.11B 10-K · filed 2021-03-01 |
| 2019-09-30 | $3.05B 10-Q · filed 2019-11-07 |
| 2019-06-30 | $3.03B 10-Q · filed 2019-08-07 |
| 2019-03-31 | $3.00B 10-Q · filed 2019-05-08 |
| 2018-12-31 | $2.61B 10-K · filed 2020-02-26 |
| 2018-09-30 | $2.08B 10-Q · filed 2018-10-31 |
| 2018-06-30 | $2.06B 10-Q · filed 2018-08-08 |
| 2018-03-31 | $2.03B 10-Q · filed 2018-05-03 |
| 2017-12-31 | $2.01B 10-K · filed 2019-02-28 |
| 2017-09-30 | $1.89B 10-Q · filed 2017-11-01 |
| 2017-06-30 | $1.52B 10-Q · filed 2017-08-03 |
| 2017-03-31 | $1.51B 10-Q · filed 2017-05-04 |
| 2016-12-31 | $1.50B 10-K · filed 2018-03-01 |
| 2016-09-30 | $1.49B 10-Q · filed 2016-11-07 |
| 2016-06-30 | $1.14B 10-Q · filed 2016-08-09 |
| 2016-03-31 | $1.10B 10-Q · filed 2016-05-05 |
| 2015-12-31 | $1.09B 10-K · filed 2017-02-28 |
| 2015-09-30 | $957.61M 10-Q · filed 2015-11-05 |
| 2014-12-31 | $926.77M 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |